{
  "id": [
    "29382901"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "29382901"
  ],
  "pmcid": [
    "PMC5789983"
  ],
  "doi": [
    "10.1038/s41598-018-20325-0"
  ],
  "title": [
    "Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry."
  ],
  "authorString": [
    "Tavares ABMLA, Lima Neto JX, Fulco UL, Albuquerque EL."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Tavares ABMLA"
          ],
          "firstName": [
            "Ana Beatriz M L A"
          ],
          "lastName": [
            "Tavares"
          ],
          "initials": [
            "ABMLA"
          ],
          "affiliation": [
            "Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal, RN, Brazil."
          ]
        },
        {
          "fullName": [
            "Lima Neto JX"
          ],
          "firstName": [
            "José X"
          ],
          "lastName": [
            "Lima Neto"
          ],
          "initials": [
            "JX"
          ],
          "authorId": [
            {
              "_": "0000-0001-6428-811X",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "affiliation": [
            "Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal, RN, Brazil."
          ]
        },
        {
          "fullName": [
            "Fulco UL"
          ],
          "firstName": [
            "Umberto L"
          ],
          "lastName": [
            "Fulco"
          ],
          "initials": [
            "UL"
          ],
          "affiliation": [
            "Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal, RN, Brazil."
          ]
        },
        {
          "fullName": [
            "Albuquerque EL"
          ],
          "firstName": [
            "Eudenilson L"
          ],
          "lastName": [
            "Albuquerque"
          ],
          "initials": [
            "EL"
          ],
          "authorId": [
            {
              "_": "0000-0002-1022-1048",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "affiliation": [
            "Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal, RN, Brazil. eudenilson@gmail.com."
          ]
        }
      ]
    }
  ],
  "authorIdList": [
    {
      "authorId": [
        {
          "_": "0000-0001-6428-811X",
          "$": {
            "type": "ORCID"
          }
        },
        {
          "_": "0000-0002-1022-1048",
          "$": {
            "type": "ORCID"
          }
        }
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "1"
      ],
      "volume": [
        "8"
      ],
      "journalIssueId": [
        "2635309"
      ],
      "dateOfPublication": [
        "2018 Jan"
      ],
      "monthOfPublication": [
        "1"
      ],
      "yearOfPublication": [
        "2018"
      ],
      "printPublicationDate": [
        "2018-01-01"
      ],
      "journal": [
        {
          "title": [
            "Scientific reports"
          ],
          "ISOAbbreviation": [
            "Sci Rep"
          ],
          "medlineAbbreviation": [
            "Sci Rep"
          ],
          "NLMid": [
            "101563288"
          ],
          "ISSN": [
            "2045-2322"
          ],
          "ESSN": [
            "2045-2322"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2018"
  ],
  "pageInfo": [
    "1840"
  ],
  "abstractText": [
    "Much of the recent excitement in the cancer immunotherapy approach has been generated by the recognition that immune checkpoint proteins, like the receptor PD-1, can be blocked by antibody-based drugs with profound effects. Promising clinical data have already been released pointing to the efficiency of the drug pembrolizumab to block the PD-1 pathway, triggering the T-lymphocytes to destroy the cancer cells. Thus, a deep understanding of this drug/receptor complex is essential for the improvement of new drugs targeting the protein PD-1. In this context, by employing quantum chemistry methods based on the Density Functional Theory (DFT), we investigate in silico the binding energy features of the receptor PD-1 in complex with its drug inhibitor. Our computational results give a better understanding of the binding mechanisms, being also an efficient alternative towards the development of antibody-based drugs, pointing to new treatments for cancer therapy."
  ],
  "affiliation": [
    "Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal, RN, Brazil."
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Electronic"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "Research Support, Non-U.S. Gov't",
        "research-article",
        "Journal Article"
      ]
    }
  ],
  "meshHeadingList": [
    {
      "meshHeading": [
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "T-Lymphocytes"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "ME"
                  ],
                  "qualifierName": [
                    "metabolism"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Humans"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Neoplasms"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "ME"
                  ],
                  "qualifierName": [
                    "metabolism"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "TH"
                  ],
                  "qualifierName": [
                    "therapy"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Antibodies, Monoclonal"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Immunotherapy"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "MT"
                  ],
                  "qualifierName": [
                    "methods"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Antibodies, Monoclonal, Humanized"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Programmed Cell Death 1 Receptor"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "AI"
                  ],
                  "qualifierName": [
                    "antagonists & inhibitors"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  ],
  "chemicalList": [
    {
      "chemical": [
        {
          "name": [
            "Antibodies, Monoclonal"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Antibodies, Monoclonal, Humanized"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Programmed Cell Death 1 Receptor"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "pembrolizumab"
          ],
          "registryNumber": [
            "DPT0O3T46P"
          ]
        }
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC5789983?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC5789983"
          ]
        },
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1038/s41598-018-20325-0"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "N"
  ],
  "citedByCount": [
    "1"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "N"
  ],
  "license": [
    "cc by"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCompletion": [
    "2018-12-11"
  ],
  "dateOfCreation": [
    "2018-02-01"
  ],
  "firstIndexDate": [
    "2018-02-01"
  ],
  "dateOfRevision": [
    "2019-01-30"
  ],
  "electronicPublicationDate": [
    "2018-01-30"
  ],
  "firstPublicationDate": [
    "2018-01-30"
  ]
}